Form 4: FibroBiologics CSO Hamid Khoja Receives Stock Option Grant

Chief Scientific Officer Hamid Khoja was granted options to purchase 61,607 shares of FibroBiologics common stock.

Summary

• Hamid Khoja, Chief Scientific Officer of FibroBiologics, Inc., received a grant of 61,607 stock options.
• The options have an exercise price of $1.38 per share.
• The grant date is May 4, 2026, with an expiration date of May 4, 2036.
• Vesting follows a schedule where 25% vests on the first anniversary, followed by 36 equal monthly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Aligns the interests of the Chief Scientific Officer with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the reporting person remaining in continuous service with the company.

Future Outlook

The grant is subject to a multi-year vesting schedule, incentivizing the officer's continued tenure through May 2036.

Industry Context

StockSavvy.ai notes that equity grants to key scientific personnel are standard practice in the biotechnology sector to retain talent and align leadership with R&D milestones.

Comparison to Industry Standards

• The use of a 4-year vesting schedule with a 1-year cliff is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of 1/4th of the options on May 4, 2027.
• Continued monthly vesting of remaining options over the subsequent 36 months.

Key Dates

Keywords

FibroBiologics, FBLG, Form 4, Insider Trading, Stock Options, Executive Compensation